📢 Stocks Trending NOW: #DIS #ONDS #CSCO #BITF #NVVE #JD #BABA #TNMG #SGBX #LPTX

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #EXE 11.0x
2. #HAL 8.6x
3. #LPTX 7.3x
4. #CSCO 6.3x
5. #ONON 5.8x

#OptionFlow #OptionsTrading #Trading

Most Searched, Wednesday November 12, 2025 – Crystal Equity Research

Most searched small-cap stocks, Wed Nov 12th - #LWLG #GPUS #BLMZ #NVTS #CMBM #RXRX #HIVE #BTBT #EOSE #CMCT #DNN #ONDS #BITF #QUBT #PLUG #LPTX #INDP #ENGN #BTCS #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#EXE, #HAL, #LPTX, #ONON, #CL

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #LPTX 5.2x
2. #CWAN 3.2x
3. #PAAS 2.4x
4. #KDP 2.3x
5. #ONON 2.3x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#LPTX, #KDP, #SONY, #ONON, #TME

#OptionFlow #OptionsTrading #Trading

JUST IN: ( NASDAQ: #LPTX ) Expected US Company Earnings on Wednesday, November 12th, 2025

Leap Therapeutics purchased $50 million worth of #ZEC tokens.

#LPTX = +100%

PRISM Mid-Day Movers:
Critical Metals (NASDAQ: #CRML) +70% on $35M funding for Greenland project & U.S. stake interest.
Leap Therapeutics (NASDAQ: #LPTX) +64% after $58.9M crypto-backed funding & biotech boost.
Other movers: #HIVE +21%, #RVPH +16%, #SKYE -54%.
prismmarketview.com/prism-mid-da...

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy Leap Therapeutics (Nasdaq:LPTX) announced a $58,888,888 PIPE led by Winklevoss Capital to initiate a digital asset treasury strategy. The transaction includes 95,849,353 purchased shares or pre-funded warrants and 71,887,008 warrants exercisable at $0.5335 per share, implying an aggregate exercise price per Unit of $0.61439. Winklevoss Capital will provide capital and strategic support and has the right to nominate two board members, including the board chair, as Leap expands its board to 12 members. A portion of proceeds will fund therapeutic programs including FL-501 and sirexatamab. Closing expected on or about October 8, 2025, subject to customary conditions.

#LPTX Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

www.stocktitan.net/news/LPTX/leap-therapeut...

Leap Therapeutics Slashes R&D Spending | The Motley Fool

#LPTX #d63a5000-9860-4c39-83f9-9028311c6c3b #data-news

Origin | Interest | Match

Leading Indicators, Tuesday August 5, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Tue Aug 5th - #XTKG #TRUE #SEAT #PTLO #LPTX #JWEL #ICHR #BINI #AYRO #TIC #SCS #HZAC #EPC #AGL - More: crystalequityresearch.com/leading-indi... - #smallcap

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives Leap Therapeutics (LPTX) reported updated results from its Phase 2 DeFianCe study of sirexatamab in colorectal cancer, showing significant benefits in specific patient subgroups. The drug demonstrated improved progression-free survival and response rates, particularly in DKK1-high patients, VEGF-naïve patients, and those with liver metastases. However, due to financial constraints, the company is winding down the trial and implementing a 75% workforce reduction. Leap's Board has initiated a strategic alternatives review process, including potential sale or partnership opportunities for sirexatamab and FL-501. The company had $32.7M cash as of March 2025, with restructuring costs estimated at $3.2M. Raymond James has been engaged as financial advisor for the strategic evaluation process.

#LPTX Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

www.stocktitan.net/news/LPTX/leap-therapeut...

Leap Therapeutics Reports First Quarter 2025 Financial Results Leap Therapeutics (LPTX) reported Q1 2025 financial results and key developments. The company's lead drug sirexatamab (DKN-01) showed positive Phase 2 DeFianCe study results in colorectal cancer, demonstrating 32% higher overall response rate and 3.5-month longer progression-free survival in DKK1-high patients. In VEGF-naïve patients, it showed 22% higher ORR and 2.6-month longer PFS. The company presented preclinical data for FL-501, their GDF-15 neutralizing antibody, at AACR 2025. Due to market conditions, Leap implemented a strategic restructuring, reducing workforce by 50% to focus on sirexatamab development. Q1 2025 financial results showed a net loss of $15.4 million, up from $13.8 million in Q1 2024, with cash reserves of $32.7 million as of March 31, 2025.

#LPTX Leap Therapeutics Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/LPTX/leap-therapeut...

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results Leap Therapeutics (LPTX) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical trials. The company's Phase 2 DeFianCe study of sirexatamab showed promising results in colorectal cancer treatment, with a 32% higher overall response rate and 3.5-month longer progression-free survival in patients with high DKK1 levels.Financial results show a net loss of $67.6 million for 2024, improved from $81.4 million in 2023. Research and development expenses decreased to $57.2 million from $73.2 million, while general and administrative expenses reduced to $12.8 million from $13.8 million. The company maintains $47.2 million in cash as of December 31, 2024.The company sees a significant market opportunity, with approximately 30,000 second-line CRC patients in the US and 160,000 in the next 7 largest markets. Leap has engaged a financial advisor to explore business development opportunities for sirexatamab.

#LPTX Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/LPTX/leap-therapeut...

Breakthrough: New Cancer Drug Delivers 3.5-Month Survival Benefit in Colorectal Cancer Study Latest clinical data reveals 32% higher response rate and 3.5-month survival benefit in colorectal cancer patients with high DKK1 levels. Full analysis inside.

#LPTX Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

www.stocktitan.net/news/LPTX/leap-therapeut...

Revolutionary Cancer Drug Achieves Double the Normal Response Rate in Targeted Patient Group Leap Therapeutics reports promising 35% response rate in colorectal cancer trials, with up to 48% efficacy in high DKK1 patients. Phase 3 trials planned despite setback in gastric cancer program.

#LPTX Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

www.stocktitan.net/news/LPTX/leap-therapeut...

#LPTX Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/LPTX/leap-therapeut...